Low Levels of Electromagnetic Fields to Treat Advanced Cancer (ADLG3)

Expanded access is no longer available for this treatment.
Sponsor:
Information provided by:
Pasche, Boris, M.D.
ClinicalTrials.gov Identifier:
NCT00805337
First received: December 5, 2008
Last updated: December 6, 2008
Last verified: December 2008
  Purpose

Following the discovery of tumor-specific frequencies in patients with advanced cancer, compassionate treatment with tumor-specific frequencies administered at levels that are significantly below the levels generated by cell phone will be offered to patients with limited therapeutic options.


Condition Intervention
Cancer
Device: Intrabuccally-administered amplitude-modulated RFEM

Study Type: Expanded Access     What is Expanded Access?
Official Title: Compassionate Treatment of Advanced Cancer With Amplitude-Modulated Electromagnetic Fields

Resource links provided by NLM:


Further study details as provided by Pasche, Boris, M.D.:

Intervention Details:
    Device: Intrabuccally-administered amplitude-modulated RFEM
    Generation of amplitude-modulated electromagnetic fields: the device consists of a battery-driven radiofrequency (RF) electromagnetic field generator connected to a 1.5 meter long 50 Ohm coaxial cable, to the other end of which a spoon-shaped mouthpiece made of steel is connected with the inner conductor. The RF source of the device corresponds to a high-level amplitude-modulated class C amplifier operating at 27.12 MHz. The modulation frequency can be varied between 0.01 Hz and 150 kHz with a modulation depth of 85 ± 5%. The RF output is adjusted to 100 mW into a 50 Ohm load using a sinusoidal modulated test signal, which results in an emitting power identical to that of the device used in the treatment of insomnia (Pasche et al 1996, 19:327-336).
    Other Name: Symtonic TheraBionic
Detailed Description:

We have previously shown that the intrabuccal administration of low and safe levels of electromagnetic fields, amplitude-modulated at a frequency of 42.7 Hz by means of a battery-powered portable device modifies the electroencephalographic activity of healthy subjects (1, 2) and is associated with subjective and objective relaxation effects (3). These results prompted us to study the effects of the 42.7 Hz frequency in patients suffering from insomnia. A randomized control trial did not reveal any difference between 42.7 Hz treatment and placebo (4) but sequential administration of four insomnia-specific frequencies, including 42.7 Hz, resulted in a significant decrease in sleep latency and a significant increase in total sleep time in patients suffering from chronic insomnia (5). Dosimetric studies have shown that the amount of electromagnetic fields delivered to the brain of patients with this approach is 100 to 1000 times lower than the amount of electromagnetic fields delivered by handheld cellular phones and do not result in any heating effect within the brain (4). The U.S. FDA has determined that such a device is not a significant risk device. Lastly, a long-term follow-up survey of 807 patients who have received this therapy revealed that the rate of adverse reactions were low and were not associated with increases in the incidence of malignancy or coronary heart disease (6).

Given the advantageous safety profile of athermal, non-ionizing radiofrequency electromagnetic fields and the emerging evidence that low levels of electromagnetic or electric fields may modify the growth of tumor cells (7-9), we decided to test the hypothesis that low levels of electromagnetic fields modulated at tumor-specific frequencies may alter the growth of human malignancies. We have developed a novel patient-based biofeedback method with the goal to identify cancer-specific frequencies and have examined patients with this approach. Following identification of such frequencies in a total of 163 patients, we will offer compassionate treatment to 28 patients with advanced cancer and limited palliative therapeutic options.

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Diagnosis of cancer with advanced disease and limited therapeutic options

Exclusion Criteria:

  • Any patient with curative treatment options
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Boris Pasche, Cabinet Avenue de la gare 6, CH-1003-Lausanne
ClinicalTrials.gov Identifier: NCT00805337     History of Changes
Other Study ID Numbers: ADLG3
Study First Received: December 5, 2008
Last Updated: December 6, 2008
Health Authority: Switzerland: Laws and standards

Keywords provided by Pasche, Boris, M.D.:
Cancer amplitude-modulated electromagnetic fields

ClinicalTrials.gov processed this record on October 21, 2014